OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沉默红牛完成签到,获得积分10
刚刚
干净的琦发布了新的文献求助150
刚刚
1秒前
17686418536发布了新的文献求助10
3秒前
annie完成签到,获得积分10
4秒前
4秒前
清脆画板发布了新的文献求助10
4秒前
王祥瑞完成签到,获得积分10
4秒前
hzh完成签到,获得积分20
4秒前
5秒前
5秒前
5秒前
ss完成签到,获得积分10
6秒前
科研通AI6.2应助mjn404采纳,获得10
6秒前
6秒前
7秒前
科研通AI6.3应助辛勤语海采纳,获得10
7秒前
8秒前
8秒前
wang0708发布了新的文献求助10
9秒前
烟里戏发布了新的文献求助10
11秒前
hzh发布了新的文献求助10
11秒前
ZZZFK发布了新的文献求助10
11秒前
立冬发布了新的文献求助10
11秒前
莫若舞完成签到,获得积分10
12秒前
12秒前
12秒前
12秒前
Sxin发布了新的文献求助10
12秒前
Jason发布了新的文献求助30
12秒前
虚幻穆发布了新的文献求助10
12秒前
可萨利亚发布了新的文献求助10
13秒前
WAHAHAoo完成签到,获得积分10
14秒前
锅里有虾发布了新的文献求助10
15秒前
善学以致用应助小男孩采纳,获得10
16秒前
优秀恶天发布了新的文献求助10
17秒前
烂漫母鸡发布了新的文献求助10
17秒前
17秒前
17秒前
18秒前
高分求助中
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Propeller Design 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Handbook of pharmaceutical excipients, Ninth edition 1500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6010872
求助须知:如何正确求助?哪些是违规求助? 7558101
关于积分的说明 16135423
捐赠科研通 5157703
什么是DOI,文献DOI怎么找? 2762473
邀请新用户注册赠送积分活动 1741102
关于科研通互助平台的介绍 1633548